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Abstract: Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin
with a poor prognosis and an apparent increase in incidence. Due to its rarity, evidence-based
guidelines are limited, and there is a lack of awareness among clinicians. This review constitutes
the consensus management recommendations developed by the Danish MCC expert group and is
based on a systematic literature search. Patients with localized disease are recommended surgical
excision and adjuvant radiotherapy to the primary site; however, this may be omitted in patients
with MCC with low risk features. Patients with regional lymph node involvement are recommended
complete lymph node removal and adjuvant radiotherapy in case of extracapsular disease. Metastatic
disease was traditionally treated with chemotherapy, however, recent clinical trials with immune
therapy have been promising. Immune checkpoint inhibitors targeting the programmed cell death
protein 1(PD-1)/programmed death-ligand 1(PD-L1) axis should therefore be strongly considered
as first-line treatment for fit patients. A 5-year follow-up period is recommended involving clinical
exam every 3 months for 2 years and every 6 months for the following 3 years and PET-CT one to two
times a year or if clinically indicated. These national recommendations are intended to offer uniform
patient treatment and hopefully improve prognosis.
Keywords: Merkel cell carcinoma; diagnosis; treatment; review; guideline
1. Introduction
Merkel cell carcinoma (MCC) is a rare and highly aggressive neuroendocrine malignancy of the skin.
Research in MCC has recently gained traction due to successful clinical trials with immune checkpoint
Cancers 2020, 12, 554; doi:10.3390/cancers12030554 www.mdpi.com/journal/cancers
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inhibitors and the discovery of the Merkel cell polyoma virus (MCPyV) [1,2]. The incidence in Denmark
has increased 5.4-fold from 0.06 cases/100,000 in 1986 to 0.31 cases/100,000 in 2002 [3]. The median age
of patients at diagnosis is 77 years, with the majority being male (62%) [4]. MCC is primarily caused
by UV-radiation (24%) and/or the presence of MCPyV (76%) [1,5,6]. Immunosuppression also plays
a role and increases the risk of MCC, as seen in individuals with chronic lymphatic leukemia (30-fold),
the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS, 13-fold) and
organ transplants recipients (10-fold) [7]. Currently, the 5-year overall survival of MCC is approximately
40%, making it more deadly than melanoma [8]. The current review constitutes the national Merkel cell
carcinoma management recommendations developed by the Danish MCC expert group.
2. Diagnosis
2.1. Clinical Features
MCC usually presents as a nonspecific, firm, rapidly growing, painless red, purple or pink exophytic
cutaneous nodule (Figure 1) [9]. The tumor is most often located in the head and neck area (43%), followed
by the extremities (39%) [8]. As the presentation is often nonspecific and clinical diagnosis is only correct in
1% of cases, the AEIOU acronym has been developed to increase diagnostic accuracy by defining clinical
features of MCC: Asymptomatic/lack of tenderness, Expanding rapidly, Immune suppression, Older than
50 years, and Ultraviolet-exposed site on a person with fair skin. Approximately 89% of patients have ≥3
of these features. Common benign misdiagnoses include cyst/acneiform lesion, lipoma, fibroma, vascular
lesion or insect bite [9].
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2.2. Pathology
Histology: CC is often located in the dermis extending into the subcutaneous tissue. The cells are
small, uniform and basaloid with granulated chromatin, scant cytoplasm and high mitotic rates [10].
Necrosis, increased vascularization, immune cell infiltration, solar elastosis and collision tu ors
(squamous cell carcinoma, basal cell carcinoma, actinic keratosis, Bowen disease) are common features [10].
Having the appearance of a small round blue cell tumor, MCC has many differential diagnoses, the most
important being basal and squamous cell carcinomas, metastatic small cell carcinomas from other sites,
melano a, non-Hodgkin lympho as and anaplastic adnexal carcinomas [11].
Im unohistochemistry (Table 1): MCC most commonly expresses epithelial markers, more
specifically CK20, with a paranuclear dot-like staining. It shows neuroendocrine features with expression
of neuroendocrine markers such as CD56 (88.2% positivity), chromogranin A (84.1% positivity) and
synaptophysin (92% positivity) [12].
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Table 1. Immunohistochemical markers in MCC and common differential diagnosis (Llombart et al. [11]).
Cancer Type CK (AE1/AE3) CK20 CK7 TTF-1 CD56 LCA S-100 CD-99 Chromogranin A Synaptophysin
Merkel cell carcinoma + + − − + − − + + +
Small cell lung cancer + − + + + − − + + +
Lymphoma − − − − − + − − − −
Melanoma −/(+) − − − + − + − − −
Ewing’s sarcoma −/(+) − − − + − - + −/(+) −/(+)
MCC is negative for leukocyte common antigen (CD45, in contrast to lymphoma), S-100 (in contrast
to melanoma), CK7 and TTF-1 (in contrast to small cell lung cancer) [12,13].
MCC diagnosis is based on histological features combined with CK20 expression and TTF-1
negativity. A subgroup of MCC does not stain accordingly, as 12.6% of MCC are CK20 negative, while
7% express TTF-1 [12]. CM2B4, which targets the MCV-large T antigen, may also be useful in diagnostics
of virus-positive MCC (sensitivity 88.2%; specificity 94.3%) [6].
Proposed immunohistochemical panel: CK(AE1/AE3), CK20, CK7, TTF-1, CD45, S-100, CD-99 and
neuroendocrine markers, such as synaptophysin, chromogranin A and CD56. In case of a nonconclusive
result of the immunohistochemical panel, it may be necessary to do supplementary staining according to
differential diagnosis.
Sentinel node (SN) protocol: A formalin-fixed SN will be split through the hilum and optionally
further cut into parallel slices. The paraffin-embedded tissue slices will be cut in six serial steps
with 50 µm intervals with a HE and CK(AE1/AE3) stained section at each level [14]. Isolated tumor
cells within a lymphatic channel in the parenchyma of a lymph node, or its capsule, are classified as
a metastasis.
Pathology report content should include:
Histopathological parameters: Macroscopic tumor diameter (microscopic in case of no clinical
estimation, horizontal, in mm); Margin status (distance from lateral and deep resection margins,
macroscopic and/or microscopic estimation, in mm); Tumor thickness (from stratum granulare, or highest
tumor cell in case of ulceration, to deepest tumor cell, in mm with no decimals); Ulceration (total loss of
epidermis with vital reaction, present/absent); Lymphovascular invasion (LVI) and perineural invasion
(present/absent); Level of invasion (extracutaneous extension to muscle/fascia/cartilage/bone); Collision
tumors (description if present).
Immunohistochemical analyses: Ki67 (% of tumor cells, estimate in 10% intervals if image counting
tools are not available (more reproducible than hotspot counting)); Tumor infiltrating lymphocytes
(number of CD8 positive lymphocytes per HPF); Viral status (MCPyV is positive when >1% of tumor
cells stain independently of intensity when using the immunohistochemical clone CM2B4).
Sentinel lymph node status: Maximum diameter of the metastasis is reported, as well as number of
involved/removed lymph nodes and extracapsular extension (presence of nodal metastasis extending
through the lymph node capsule and into adjacent tissue) [15]; In-transit metastasis (present/absent):
A discontinuous tumor distinct from the primary lesion and located between the primary lesion and
the draining regional lymph nodes or distal to the primary lesion (Figure S1).
3. Work-Up & Staging
3.1. Work-Up
Patients should undergo full clinical skin and lymph node investigation with/without ultrasound
(US) of the regional lymph node basin (Figure 2). Baseline F18-FDG whole-body positron emission
tomography-computed tomography (PET-CT) scan may exclude differential diagnosis (mainly small cell
lung cancer), lead to upstaging in 16% of patients and change management in up to 37% (Table 2) [16,17].
Until more data are produced, baseline PET-CT may be considered for all MCC patients.
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Table 2. Impact of staging with PET-CT adapted from Hawryluk et al. [16].
Stage Patients Upstaged by PET/CT Patients Upstaged by PET/CT (%)
IA 0/12 0%
IB 0/5 0%
IIA 0/3 0%
IIB 0/5 0%
IIIA 1/22 4.5
IIIB 4/8 50%
IV 5/5 100%
Patients without clinically involved lymph nodes are recommended sentinel lymph node biopsy
(SLNB), as 24–32% of these pat ents harbor clinically occult, microscopic regiona metastasis [18–20].
Risk increases with tumor diam ter, but patients with tumors down to 0.5 cm h ve been shown to be
sentinel lymph node (SLN) positive in 14% [21]. SLNB should be carried out at the same time as wid
excision to avoid inaccuracy and mi imize the risk of false-negative results if perfor ed after
(15–17%) [18,22]. Patients with clinically inv lved lymph nodes should b offer US-guided
fine needle aspiration biopsy (FNAB) to confirm the diagnosis.
3.2. Staging
The current staging is based on the eighth edition of the tumor, node, metastasis (TNM) staging
system, recommend by the Union for International Cancer Control (UICC) and the American Joint
Com ittee n Cancer (Figure S1). The expected 5-year overall survival (OS) for each stage is illustrated
in Table 3 [8].
Table 3. Five-year overall survival with confidence interval (CI) [8].
Stage Clinical Staging (95% CI) Pathological Staging (95% CI)
I 45.0% (41.9–48.1%) 62.8% (59.6–65.8%)
IIA 30.9% (27.0–34.9%) 54.6% (49.3–59.7%)
IIB 27.3% (16.0–39.9%) 34.8% (25.6–44.1%)
IIIA Data lacking 40.3% (37.5–43.0%)
IIIB Data lacking 26.8% (23.4–30.4%)
IV Data lacking 13.5% (11.0–16.3%)
The eighth edition of the TNM staging system is based on 9387 MCC cases with follow-up and
staging data from 1998 to 2012 [8]. Staging can be clinical or pathological; the latter is more precise.
Patients with local disease and negative SLNs have better prognosis (76% at 5 years) than those with
clinically negative nodes (59% at 5 years) as the latter may harbor occult metastases that are not detected
at time of diagnosis if SLNB is not performed [23]. Patients with nodal disease and unknown primary
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tumor are now given similar stage as patients with any tumor and microscopic nodal involvement
(pathological stage IIIA), as patients with clinically detected nodal disease and unknown primary
tumor show improved prognosis over cases with concurrent known primary tumor (OS 42% vs. 27%,
respectively) [8].
4. Treatment
Due to the rarity of MCC, prospective clinical trials are rarely conducted. Therefore, current
treatment recommendations are mostly based on retrospective studies with few patients (Figure S2).
5. Management of the Primary Tumor
5.1. Surgery
Traditionally, the recommended excisional margin for primary tumors has been 2–3 cm [24,25].
Recent studies comparing different excision margins show that patients (n = 47) treated with 1, 2 or 3 cm
margins did not have a statistically significant difference in disease-free survival and OS [26]. Similarly,
the largest single-institution study to date (n = 240) did not demonstrate a significant difference in local
recurrence or disease-specific survival between patients treated with 1, 1.1–1.9 or >2 cm excisions [27].
Surgery-only (n = 104) with an excisional width of 1–2 cm to the tumor bed (tumor diameter < 2 cm) has
demonstrated local recurrence rates down to 1.9% [19]. However, these studies were not randomized
clinical trials so confounding by indication may be prevalent; larger excision margins may have been
used for larger tumors. Regular randomized trials testing different resection margins are warranted
but difficult to complete due to the small number of patients. A positive surgical margin is associated
with reduced OS and should lead to re-excision [28,29]. Based on the above studies, an excisional
margin of 1–2 cm is recommended.
5.2. Adjuvant Radiotherapy
Primary tumor: Radiotherapy (RT) is recommended following surgical excision [30]. In 4843 MCC
cases, the largest cohort to date, it was shown that localized MCC (stage I and II) treated with primary
surgery and adjuvant RT was associated with improved OS, compared to surgery alone (stage I: HR = 0.71,
95% CI = 0.64 to 0.80, p < 0.001; stage II: HR 0.77, 95 % CI = 0.66 to 0.89, p < 0.001) [28].
Recommended dose is 50–60 Gy at 2 Gy/d, 5 fractions per week (F/W) [31–33]. Adjuvant radiotherapy
(RT) to the primary site has been shown to improve local control, and data from three pooled prospective
trials, which included 88 high-risk MCC patients, showed that pre-radiation margin status (positive/negative)
did not have an impact on time to loco-regional failure in patients receiving adjuvant RT [34]. As most MCCs
are located in the head-and-neck area, a wide surgical margin is not always feasible and should not be
pursued at all costs, but respect functionality and cosmesis, especially as adjuvant RT leads to a high degree
of local control. Administration of RT should be carried out within 3 weeks after surgery to minimize disease
progression prior to RT [35].
Adjuvant RT may be left out in patients with low-risk characteristics in their primary tumors
(Figure S3). These include small primary tumors (≤1 cm diameter), negative margin status, no LVI,
negative SLNB and no chronic immunosuppression (i.e., lymphoma/leukemia) [18,19,36]. In a small
retrospective study on patients with low-risk head-and-neck primary tumors, adjuvant RT was associated
with increased local control without a survival benefit [37]. Since all recurrences were salvaged by
radiotherapy, adjuvant RT should not routinely be recommended for this patient subgroup but discussed
per case.
Regional lymph nodes: Prophylactic regional RT is not recommended in SLNB-negative patients,
as this has not shown to reduce the regional recurrence rate [38].
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5.3. Definitive Radiotherapy—Nonresectable Disease
Definitive RT increases disease control but should be reserved for patients who are not candidates
for complete, gross resection or refuse surgical intervention. A systematic review including 23 studies
found that definitive RT to 136 primary tumor sites resulted in local recurrence rates of 7.6% with
a median follow-up time of 24 months. Definitive RT was more effective in managing local disease
at the primary tumor site, compared with the regional site (7.6% vs. 16%, p = 0.02) [39]. In terms of
survival, a study of 50 patients with local disease based on clinical examination and ultrasound treated
with definitive RT or conventional treatment (surgery and adjuvant RT) indicated no statistically
significant difference in overall (p = 0.18) or disease-free survival (p = 0.32) between the groups [40].
However, no randomized studies have evaluated the effect of primary surgery and adjuvant RT versus
definitive RT. The recommended doses are 56–60 Gy at 2 Gy/d.
Management of the primary tumor summarized:
A 1–2 cm clinical excision margin resulting in negative margins.
Adjuvant RT for primary tumors >1 cm and/or absence of low-risk characteristics (negative surgical
margin, negative SLNB, no LVI and no chronic immunosuppression). Adjuvant RT offers disease control,
but potential benefit should always be carefully weighed against morbidity and frailty of the patient.
Recommended dose: 50–60 Gy at 2 Gy/d, 5 F/W with 1–2 cm margins.
Definitive RT may be offered to patients who are not candidates for or refuse surgery.
Recommended dose: 56–60 Gy at 2 Gy/d, 5 F/W with 1–2 cm margins.
Prophylactic regional RT in SLNB-negative patients is not recommended.
6. Management of the Regional Lymph Nodes
The evidence on management of patients with nodal disease is particularly scarce, as most studies
are retrospective, have too few patients and/or short follow-up periods and often have selection bias
in patients receiving adjuvant therapy. Recent large single-institution studies suggest no difference
between SLNB-positive patients treated with radiotherapy or therapeutic lymph node dissection
(TLND) [41,42]. Patients with nodal disease have poor prognosis and high recurrence rates, compared
to patients with localized disease [8,43]. This may warrant an aggressive treatment approach, despite
lack of evidence on optimal management of patients with nodal disease.
6.1. Lymph Node Dissection and Locoregional Radiotherapy
All patients with pathologically confirmed regional lymph node metastases should be recommended
TLND, whether it be a positive SLN or a palpable/radiologically confirmed metastasis. Additionally,
TLND provides prognostic information as SLNB-positive patients with 1 or more positive non-SLNs are
associated with a significantly worse prognosis [42]. Adjuvant regional RT is associated with increased
morbidity, while the effect of adjuvant RT on OS seems less convincing, as stage III-patients (n = 2065)
treated with surgery and adjuvant RT were not shown to have a statistically significant improvement
in OS, compared to patients treated with surgery alone (p = 0.80) [28,36,41]. Indications for post-operative
regional RT may therefore be restricted to patients with extracapsular disease to achieve regional control.
The recommended doses are 50–60 Gy at 2 Gy/d, 5 F/W (Figure S3) [33]. No randomized controlled
trials have compared regional nodal surgery to regional RT. Based on the above considerations and
uncertainties, patients with nodal involvement should be evaluated individually in multidisciplinary
tumor board consultations.
6.2. Definitive Radiotherapy – Nonresectable Disease
Definitive RT offers clinically meaningful disease control and is indicated for patients, who are
not candidates for complete, gross resection or refuse surgical intervention. A systematic review and
analysis of 23 studies found that 127 regional nodal sites treated with definitive RT resulted in a 16%
recurrence rate with a median follow-up time of 24 months [39]. A prospective trial examining patients
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treated with macroscopic (n = 24) and microscopic (n = 26) nodal disease did not show a statistically
significant difference in disease-specific survival when patients were treated with definitive RT versus
TLND with/without regional RT (p = 0.9 and p = 0.7, respectively) [44]. The recommended dose to the
regional lymph nodes is 56–60 Gy at 2 Gy/d per day. Collectively, definitive RT may offer clinically
acceptable primary site and regional disease control for patients with unresectable disease or patients
with serious co-morbidity preventing surgical intervention.
6.3. Other Treatment Regimens
Adjuvant chemotherapy is not recommended for resected stage III patients due to lack of association
with improved OS (n = 2065, p = 0.71) [28]. Clinical trials with immunotherapy may be considered,
albeit more specific recommendations will await the results of clinical studies, e.g., the ADAM
trial—a randomized phase 3 trial with adjuvant avelumab in 100 stage III MCC patients [45].
Management of the regional lymph nodes summarized:
Therapeutic radical lymph node dissection is recommended in MCC patients with regional
nodal involvement.
Adjuvant regional RT should be considered in the presence of extracapsular disease.
Recommended dose: 50–60 Gy at 2 Gy/d, 5 F/W.
Definitive RT should be offered to patients, who are not candidates for or refuse surgery.
Recommended dose: 56–60 Gy at 2 Gy/d, 5 F/W.
Patients with nodal involvement should be evaluated in multidisciplinary tumor board conferences.
7. Management of Distant Metastatic Disease
Traditionally, patients with distant metastatic disease were treated with conventional chemotherapy
mainly with only palliative effect. There are currently no randomized controlled trials comparing
chemotherapy with immunotherapy, however promising clinical trials have resulted in the recommendation
of immunotherapy in the first-line setting in several recent guidelines [46,47].
7.1. Immune Checkpoint Inhibitors
Treatment with immune checkpoint inhibitors in the first-line setting is associated with response
rates of >50%; some durable responses and are well tolerated [48]. Qualitative interviews with
patients (n = 19) treated with both first-line chemotherapy and second-line treatment with the
immune checkpoint inhibitor avelumab indicate a better quality of life during avelumab treatment [49].
This may be considered in the clinical setting, as MCC patients have a high average age and often
multiple comorbidities.
Immunotherapy has been investigated in nonresectable stage IIIB and stage IV patients. There
are no known predictive factors, as investigations of specific biomarkers (tumor PD-L1 expression,
infiltrating lymphocyte PD-L1 expression, viral status, intratumoral CD8+ infiltration) have been unable
to predict clinical response [2,50]. Exclusion criteria include ECOG Performance Status ≥2, steroid
use in doses >10 mg prednisone daily, continued need of other immune suppressing agents, organ
transplant recipients (heart, lungs and liver) or autoimmune disease with risk of unmanageable flares.
7.2. Avelumab (PD-L1 Antibody)
First-line setting: Treatment with avelumab in patients (n = 29) with metastatic MCC, no prior
systemic treatment and at least 3 months-follow-up resulted in an objective response rate (ORR) of
62.1% (18/29 patients) with 4 (13.8%) complete responses (CR) and 14 (48.3%) partial responses (PR) [51].
At time of analysis, 14/18 (77.8%) of responses were ongoing with a 6-month response duration in 83%
of responding patients. Among 39 patients evaluable for safety analysis, 28/39 (71.8%) experienced
grade 1–3 treatment-related adverse events (TRAE) and 6/39 (15.4%) patients discontinued treatment.
There were no grade 4 TRAE or treatment-related deaths.
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Second-line setting: The largest clinical trial with immune therapy in stage IV MCC patients (n = 88)
who had progressed after receiving chemotherapy resulted in an ORR of 29/88 (33%), including 19
(21.6%) PR and 10 (11.4%) CR [52]. Among the responders, the majority (74%) had duration of response
of ≥1-year, while the 1-year OS rate was 52%. TRAE occurred in 62/80 (70%) of patients, including 4 (5%)
patients with grade 3 TRAE. There were no deaths related to treatment [2]. These findings resulted in
avelumab becoming the first approved drug for metastatic MCC by the Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) [53].
7.3. Pembrolizumab (PD-1 Antibody)
First-line setting: 50 stage IIIB/stage IV patients were administered pembrolizumab with an ORR
of 56% (28/50 patients) including 12 with CR and 16 with PR [54]. Of the 28 patients with a confirmed
response, the median response duration was not reached (ranged from 5.9 months to 34.5+ months)
with an estimated 24 months-progressive-free survival of 48.3%. TRAE occurred in 48 (96%) of patients,
including 14 (28%) patients with grade 3–4 TRAE. There was one treatment-related death. Pembrolizumab
is approved for MCC in the US but not in Europe.
7.4. Other Immune Checkpoint Inhibitors
Case studies and clinical trials with other immune checkpoint inhibitors such as nivolumab have
shown efficacy in treatment of metastatic MCC, but no applications for approval by the FDA or EMA
have yet been filed [55].
7.5. Chemotherapy
Chemotherapy used for metastatic MCC is associated with high response rates, but responses are
short-lived and the risk of adverse events, such as hematological toxicity and treatment-related death
is not negligible [48]. Furthermore, the impact on OS is unclear since there are no comparisons with
best supportive care. However, historical data of chemotherapy across regimens and centers over time
has not indicated a benefit [28,56].
First-line setting: Response rates range from 53–61% with a median progression-free survival of
3.1 months and duration of response <8 months [48]. Ninety-five percent of patients (n = 62) treated
may eventually develop progressive disease [57]. The primary recommended treatment regimens
include cisplatin or carboplatin in combination with etoposide, as platinum-containing regimens may
result in higher rates of complete (21% vs. 17%) and partial response (29% vs. 17%) compared with
non-platinum-containing regimens [48,58].
Second-line-setting: Response rates range from 23–45% with a median progression-free survival
of 2 months and duration of response <8 months [48].
Later-lines-setting: Chemotherapy in second-line or higher shows response rates of 10–29% with
no complete responses. The median duration of response is less than 2 months with a progression-free
survival and OS ranging from 2–3 months and 4–5 months, respectively [59,60].
Management of distant metastatic disease summarized:
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis should be strongly considered as
first-line treatment for fit patients with no contraindications.
Avelumab has been approved by the FDA and EMA, whereas pembrolizumab has only been
approved by the FDA. Small studies show effect of other checkpoint inhibitors, including nivolumab.
Immune checkpoint inhibitors are associated with high response rates, durable responses and
relatively few adverse events.
Chemotherapy is primarily recommended for fit patients with contraindications to immunotherapy
or after progression on immunotherapy (second line).
Recommended regimens are cisplatin or carboplatin in combination with etoposide.
No standard treatment can be recommended for patients progressing after chemotherapy; however,
fit patients may be candidates for clinical trials.
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8. Follow-Up
The patient follow-up exam should include full skin inspection and lymph node examinations
with/without US of the regional lymph nodes. As 90% of MCC reoccurrences are seen within 2 years,
follow-up is recommended every 3 months during this period, followed by every 6 months for the
following 3 years [61]. PET-CT is the imaging modality of choice. It may be conducted one to two
times a year or as clinically indicated [16,58]. Follow-up may be individualized based on patient risk
factors, as there is no solid evidence for the optimal follow-up strategy in MCC patients. Risk factors,
such as virus-negative and/or immune-compromised patients, may warrant closer follow-up due to
increased risk of disease progression and MCC-related death [6].
Follow-up summarized:
Five-year follow-up period: Every 3 months for the first 2 years. Every 6 months for the following
3 years.
PET-CT is performed one to two times a year or if clinically indicated.
9. Registration
MCC is a very rare skin cancer with a dismal prognosis compared even to melanoma, and therefore
a prospective systematic registration of the patients’ clinicopathological characteristics, surgical and
oncological treatments and clinical outcome is paramount to improve the patient outcome. A Danish
national database is under planning and all medical specialties involved in diagnosis and treatment of
these patients will participate in this registration.
10. Methods
The current recommendations were developed by a national, multidisciplinary expert group
involved in the management of Merkel cell carcinoma patients. A systematic literature review was
performed using a broad search with the following key word “Merkel Cell Carcinoma” in PubMed.
The literature search was performed including papers from 1998 to 2019 with exclusion of non-English
papers. Additional papers were included if found in reference lists. Relevant websites with guidelines
by other MCC groups and organizations such as the European Organisation for Research and Treatment
of Cancer and the National Comprehensive Cancer Network were also included. Where no firm
conclusions could be made based on the retrieved literature, expert consensus was obtained during
discussions in the expert group. A formal evaluation of the evidence level in the retrieved references
was not performed. The current work is the first attempt to agree on national guidelines, and future
updates will include more formal evaluation of the literature.
11. Conclusions
This review constitutes the consensus management recommendations developed by the Danish
MCC expert group and is based on a systematic literature search. MCC is rare, and there is a lack of
randomized controlled trials. Patients with localized disease are generally recommended surgical
excision with a 1–2 cm margin and adjuvant radiotherapy to the primary site. Clinically node-negative
patients should be offered sentinel node biopsy. Patients with regional lymph node involvement are
recommended complete node removal and, in case of extracapsular disease, adjuvant radiotherapy.
Definitive radiotherapy is recommended for patients not amenable for surgery. Although available
data on radiotherapy are conflicting, results from large datasets including a recent metanalysis point
to more restricted dosing, ensuring sufficient margins and lack of survival benefit in patients with
nodal involvement [28,30–32]. The latter is interpreted as a consequence of early subclinical metastatic
spread. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis should be considered as first-line
treatment for fit patients with nonresectable stage IIIB/IV disease.
Prospective comparative data on harmonized patient characteristics and treatment modalities
are needed to determine optimal treatment sequence and modus of MCC patients with primary and
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regional nodal disease. Acknowledging the facts that MCC is highly immunogenic and immunotherapy
is considered the new standard treatment in the advanced setting, the future role of immunotherapy in
MCC patients with primary and regional disease is highly awaited [45,62].
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